Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof (2)

Type
Compound(s)

Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof; NIH Internal Reference E-122-2001/0 More information is available here: http://www.ott.nih.gov/Technologies/abstractDetails.aspx?RefNo=566 Leishmania parasites are transmitted to their vertebrate hosts by infected phlebotomine sand fly bites. Sand fly saliva is known to enhance Leishmania infection, while immunity to the saliva protects against infection. This invention claims nine major salivary proteins from the sand fly vector of Leishmania major, Phlebotomus papatasi, nucleic acids encoding the proteins, vaccines comprising the proteins and/or nucleic acids, and methods of producing an immune response to prevent Leshmaniasis. The inventors have shown that one of these salivary proteins was able to protect vaccinated mice challenged with parasites plus salivary gland homogenates SGH . A DNA vaccine containing the cDNA for the same protein provided this same protection. Protection lasted at least 3 months after immunization. The vaccine produced both intense humoral and delayed-type hypersensitivity DTH reactions. B cell-deficient mice immunized with the plasmid vaccine successfully controlled Leishmania infection when injected with Leishmania plus SGH.

Disease
Leishmaniasis
Research areas
Basic research
Vaccine
Condition of use

n/a

IP information

Granted Patent Reference Number(s): HHS, Ref No. E-122-2001/0; US, Patent No. 7,964,576, Issued 21 Jun 2011; US,Patent No. 7,388,089, Issued 17 Jun 2008; HHS Ref No. E-122-2001/0; PCT, Application No. PCT/US02/19663 filed 18 Jun 2002; US, Application No. 13/102,936 filed 6May2011